Cryptococcosis – Page 4

Antifungal potential of Rhinacanthus nasutus extracts against the pathogenic fungus Cryptococcus neoformans

mycolabadmin

Researchers studied snake jasmine (Rhinacanthus nasutus), a plant used in traditional Thai medicine, to see if it could fight fungal infections caused by Cryptococcus neoformans, a dangerous pathogen that kills many people worldwide. They found that extract from the plant’s roots effectively slowed fungal growth and weakened the pathogen’s defenses by reducing its ability to produce protective melanin and capsules. Importantly, when combined with amphotericin B, a common antifungal drug, the plant extract worked even better together, suggesting it could enhance existing treatments.

Tailoring mRNA lipid nanoparticles for antifungal vaccines

mycolabadmin

Researchers are exploring mRNA vaccines, similar to those used for COVID-19, as a new approach to prevent fungal infections. These vaccines use fatty particles called lipid nanoparticles to deliver instructions to cells on how to make fungal proteins, triggering an immune response. The review discusses how to optimize these vaccines, what challenges need to be overcome, and why they might be especially useful for people with weakened immune systems who are most vulnerable to serious fungal infections.

Healthcare-associated fungal infections and emerging pathogens during the COVID-19 pandemic

mycolabadmin

During the COVID-19 pandemic, fungal infections became a serious complication in hospitalized patients, especially those receiving steroids and other immune-suppressing treatments. Common fungal pathogens like Candida and Aspergillus caused dangerous coinfections, with infection rates varying significantly by region. Current antifungal medications have significant limitations including toxicity and resistance, highlighting the urgent need for new and safer antifungal treatments.

Informing the World Health Organization Fungal Priority Pathogens List (WHO-FPPL): A collection of systematic reviews

mycolabadmin

The World Health Organization created a priority list of dangerous fungal infections affecting millions of people globally each year. Experts reviewed 19 different fungal pathogens and ranked them by how dangerous they are and how much they need research and treatment development. The list identifies which fungal infections should get the most attention from doctors, researchers, and public health officials to improve patient outcomes and reduce deaths.

Musculoskeletal Manifestations of Disseminated Fungal Infections

mycolabadmin

Fungal infections can spread to bones and joints, causing serious complications especially in people with weakened immune systems. These infections are tricky to diagnose because their symptoms are similar to bacterial infections or other diseases. Treatment typically involves antifungal medications and sometimes surgery to remove infected tissue. Early detection and aggressive treatment are crucial for better patient outcomes.

The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective

mycolabadmin

Fungal infections affect over a billion people worldwide but are often overlooked in healthcare. The World Health Organization recently created a priority list of dangerous fungi to help doctors and researchers focus their efforts. This review discusses how this list can improve diagnosis, testing, and treatment of fungal infections across Europe, while also highlighting the need for better training and awareness among healthcare workers.

Plants, fungi, and antifungals: A little less talk, a little more action

mycolabadmin

Plants and fungi communicate through small chemical molecules, and scientists are discovering that understanding this dialogue could lead to new antifungal medicines. Researchers found that a plant hormone called strigolactone affects a specific fungal protein involved in nutrient uptake, suggesting this could be a target for new drugs. By using baker’s yeast as a laboratory model, scientists can study how fungal cells respond to plant chemicals and identify new ways to fight dangerous fungal infections that are becoming resistant to current treatments.

Feline Cryptococcosis due to Cryptococcus gattii VGII (Recently Renamed as C. deuterogattii) in an FIV-Positive Cat With Demodicosis From Manaus, Central Amazon, Brazil

mycolabadmin

A 20-month-old cat from Brazil’s Amazon region presented with nasal discharge, skin lesions, and a neck mass and was diagnosed with cryptococcosis caused by a dangerous fungus called C. deuterogattii. The cat was also infected with feline immunodeficiency virus (FIV), which weakened its immune system and made it vulnerable to the fungal infection. Treatment with the antifungal medication fluconazole successfully cured the infection within 8 weeks, and the cat made a full recovery.

Strengthening Fungal Infection Diagnosis and Treatment: An In-depth Analysis of Capabilities in Honduras

mycolabadmin

This study examined how well healthcare facilities in Honduras can diagnose and treat serious fungal infections. Researchers surveyed laboratories and hospitals to find out what diagnostic tools and antifungal medications were available. The findings showed that while basic tests like microscopy were common, advanced techniques were rare, and many important antifungal drugs were difficult to access. The study recommends improving training, building better laboratories, and making essential medications more available.

ESCMID-EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance

mycolabadmin

This survey examined how well hospitals in Belgium, the Netherlands, and Luxembourg can diagnose and treat serious fungal infections, which are particularly dangerous for people with weakened immune systems. The researchers found that while most hospitals can test fungal samples, not all have access to all necessary diagnostic tools, especially tests for detecting resistant fungi and identifying fungal co-infections. Many hospitals outsource their testing to other facilities, which can delay diagnosis and treatment, and some hospitals lack access to all recommended antifungal medications.

Disease: Cryptococcosis